Role of Microbial Agents in Pulmonary Fibrosis

Yale J Biol Med. 2017 Jun 23;90(2):219-227. eCollection 2017 Jun.

Abstract

Pulmonary fibrosis is a form of lung disease that develops due to aberrant wound-healing following repeated alveoli injury in genetically susceptible individuals, resulting in chronic inflammation, excess deposition of the extracellular matrix components, mainly collagen, and scarring of lung tissue. In addition to irradiation, environmental agents such occupational inhalants, and chemotherapeutic agents, microbial agents also play a role in the etiology of the disease. While viruses have received the most attention, emerging evidence suggest that bacteria and fungi also play a part in the etiology of pulmonary fibrosis. Furthermore, successful use of antibiotics, antiviral and antifungal drugs in several studies to attenuate fibrosis progression is also an indication of microbial involvement in the pathogenesis of the disease and could be a promising therapeutic modality for treating pulmonary fibrosis initiated or exacerbated by infectious agents.

Keywords: Idiopathic Pulmonary Fibrosis; Microbial agents; Pulmonary Fibrosis.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Anti-Infective Agents / therapeutic use
  • Bacterial Infections / complications
  • Disease Models, Animal
  • Humans
  • Mice
  • Mycoses / complications
  • Pulmonary Fibrosis / etiology*
  • Pulmonary Fibrosis / microbiology
  • Pulmonary Fibrosis / prevention & control
  • Vaccination
  • Virus Diseases / complications

Substances

  • Anti-Infective Agents